



OPEN ACCESS

EDITED AND REVIEWED BY
Jill Kolesar,
University of Kentucky, United States

*CORRESPONDENCE
Zhigang Hu
✉ huzg_2000@126.com

†These authors have contributed
equally to this work

RECEIVED 12 July 2023
ACCEPTED 24 July 2023
PUBLISHED 31 July 2023

CITATION
Xia M, Wang S, Qi Y, Long K, Li E, He L,
Pan F, Guo Z and Hu Z (2023)
Corrigendum: Inhibition of O-GlcNAc
transferase sensitizes prostate
cancer cells to docetaxel.
Front. Oncol. 13:1257404.
doi: 10.3389/fonc.2023.1257404

COPYRIGHT
© 2023 Xia, Wang, Qi, Long, Li, He, Pan, Guo
and Hu. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel

Mingyue Xia[†], Shuyan Wang[†], Yannan Qi[†], Kaili Long, Enjie Li,
Lingfeng He, Feiyan Pan, Zhigang Guo and Zhigang Hu*

Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing
Normal University, Nanjing, China

KEYWORDS

OGT, chemotherapy, docetaxel, miR-140, prostate cancer

A corrigendum on

[Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel](#)

by Xia M, Wang S, Qi Y, Long K, Li E, He L, Pan F, Guo Z and Hu Z (2022) *Front. Oncol.* 12:993243. doi: 10.3389/fonc.2022.993243

Error in Figure/Table

In the published article, there was an error in [Figure 2C](#) as published. The panel in the bottom left of the figure was misused due to an error in the final assembly of [Figure 2](#). The corrected [Figure 2C](#) and its caption “Knockdown of OGT sensitizes PC3 and DU145 cells to docetaxel” appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 2

Knockdown of OGT sensitizes PC3 and DU145 cells to docetaxel. (A) The down-regulation of OGT and O-GlcNAc by sh-OGT plasmids was detected by Western blotting. (B) CCK8 assays using OGT-KD stable cell lines treated with docetaxel in PC3 and DU145. Data are expressed as the mean \pm standard deviation (SD), n=3 per group. (C) Knockdown of OGT sensitizes PC3 and DU145 cells to docetaxel. (D) Annexin V/PI staining and flow cytometry assay of control or OGT-KD cells with different drug treatments. (E) Western blot (WB) analysis of BAX and caspase-3 in control or OGT-KD PC3 and DU145 cells treated with various concentrations of docetaxel. All statistical data are presented as the mean \pm SD. *p < 0.05; **p < 0.01; ***p < 0.001 (Student's t-test).

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.